These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. Zádor F; Kocsis D; Borsodi A; Benyhe S Neurochem Int; 2014 Feb; 67():14-22. PubMed ID: 24508403 [TBL] [Abstract][Full Text] [Related]
4. Stabilization of functional recombinant cannabinoid receptor CB(2) in detergent micelles and lipid bilayers. Vukoti K; Kimura T; Macke L; Gawrisch K; Yeliseev A PLoS One; 2012; 7(10):e46290. PubMed ID: 23056277 [TBL] [Abstract][Full Text] [Related]
5. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Pei Y; Mercier RW; Anday JK; Thakur GA; Zvonok AM; Hurst D; Reggio PH; Janero DR; Makriyannis A Chem Biol; 2008 Nov; 15(11):1207-19. PubMed ID: 19022181 [TBL] [Abstract][Full Text] [Related]
6. Recombinant Expression and Purification of Cannabinoid Receptor CB Yeliseev AA Methods Mol Biol; 2021; 2268():61-76. PubMed ID: 34085261 [TBL] [Abstract][Full Text] [Related]
7. Identification and biochemical analyses of selective CB Scott CE; Tang Y; Alt A; Burford NT; Gerritz SW; Ogawa LM; Zhang L; Kendall DA Eur J Pharmacol; 2019 Jul; 854():1-8. PubMed ID: 30951717 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563 [TBL] [Abstract][Full Text] [Related]
10. Thermostability of a recombinant G protein-coupled receptor expressed at high level in mammalian cell culture. Yeliseev A; van den Berg A; Zoubak L; Hines K; Stepnowski S; Williston K; Yan W; Gawrisch K; Zmuda J Sci Rep; 2020 Oct; 10(1):16805. PubMed ID: 33033368 [TBL] [Abstract][Full Text] [Related]
12. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Raitio KH; Salo OM; Nevalainen T; Poso A; Järvinen T Curr Med Chem; 2005; 12(10):1217-37. PubMed ID: 15892633 [TBL] [Abstract][Full Text] [Related]
13. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S Neurochem Int; 2008 Jan; 52(1-2):321-8. PubMed ID: 17698254 [TBL] [Abstract][Full Text] [Related]
14. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105 [TBL] [Abstract][Full Text] [Related]
15. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Lavey BJ; Kozlowski JA; Hipkin RW; Gonsiorek W; Lundell DJ; Piwinski JJ; Narula S; Lunn CA Bioorg Med Chem Lett; 2005 Feb; 15(3):783-6. PubMed ID: 15664857 [TBL] [Abstract][Full Text] [Related]
16. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Marini P; Cascio MG; King A; Pertwee RG; Ross RA Br J Pharmacol; 2013 Jun; 169(4):887-99. PubMed ID: 23711022 [TBL] [Abstract][Full Text] [Related]
17. Cannabinoid receptor binding to membrane homogenates and cannabinoid-stimulated [35S]GTPgammaS binding to membrane homogenates or intact cultured cells. Breivogel C Methods Mol Med; 2006; 123():149-62. PubMed ID: 16506406 [TBL] [Abstract][Full Text] [Related]
18. Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors. Strange PG Br J Pharmacol; 2010 Nov; 161(6):1238-49. PubMed ID: 20662841 [TBL] [Abstract][Full Text] [Related]
19. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654 [TBL] [Abstract][Full Text] [Related]
20. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Berglund BA; Boring DL; Wilken GH; Makriyannis A; Howlett AC; Lin S Prostaglandins Leukot Essent Fatty Acids; 1998 Aug; 59(2):111-8. PubMed ID: 9774174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]